Faruqi and Faruqui, LLP Logo
Share this page

Otonomy, Inc. (OTIC)

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Otonomy, Inc. (“Otonomy” or the “Company”) (NASDAQ: OTIC).

On August 30, 2017, Otonomy announced that its Phase 3 clinical trial of OTIVIDEX in patients with Ménière’s disease missed its primary endpoint.  The Company also announced an immediate suspension of all development activities for OTIVIDEX.  According to Reuters, in a webcast earlier today the company said, “At this point, we have no explanation for the unequivocal negative result.”

On this news, Otonomy’s share price declined.

If you invested in Otonomy stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

 

 

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Otonomy, Inc. (OTIC)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 08/30/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.